Advanced Ocular Drug Delivery
A special issue of Pharmaceutics (ISSN 1999-4923).
Deadline for manuscript submissions: closed (15 December 2017) | Viewed by 52543
Special Issue Editors
Interests: biomaterials for drug delivery and tissue engineering
Interests: formulation and drug delivery; biomaterials
Special Issue Information
Dear Colleagues,
Because of the presence of various static, dynamic and metabolic ocular barriers, the delivery of drugs to the targeted sites of action in the eye is often very challenging and requires interdisciplinary approaches involving basic, applied and clinical sciences. In recent years, increasing progress has been made to develop novel and safe materials, devices and methods to overcome ocular barriers to deliver therapeutic agents to targeted sites in the eye. This Special Issue invites original technical papers and reviews to discuss the broad scope of recent developments, future directions, possible challenges, and regulatory and ethical issues in advancing ocular drug delivery for clinical and commercial translation. The focus is on, but not limited to biomaterials; nanotechnology; personalized ophthalmology; theranostics; ocular disease targets; biomarkers; ocular transport; ocular pharmacokinetics; industrial development; regulatory and ethical considerations; clinical studies; intellectual property; and commercialization.
Prof. Dr. Tao L. Lowe
Dr. Dileep Reddy Janagam
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Ocular drug delivery
- Ocular barriers
- Biomaterials
- Nanotechnology
- Personalized ophthalmology
- Theranostics
- Disease targets
- Biomarkers
- Ocular transport
- Ocular pharmacokinetics
- Clinical studies
- Regulatory and ethical considerations
- Intellectual property
- Commercialization
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.